ClinicalTrials.gg
CompletedNCT05919823UNITE-001Updated Dec 17, 2025Results posted

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 28 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
9th of 20
202 · median 178
Started
2023
the only one that year
Phase 3
14 of 20
4 open now
Registered
9th of 20
by date
Lead sponsor
7 of 20
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 9th largest by enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects with DSM-5 Schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is Chinese national, aged 18 to 65 years, inclusive, at screening.
  2. Subject is capable of providing written .
  3. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the and MINI.
  4. Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening.

    1. The subject requires hospitalization for this acute exacerbation or relapse of psychotic symptoms at screen.
    2. If already an inpatient at screening, hospitalization has to be ≤2 weeks for the current exacerbation at the time of screening.
  5. PANSS total score between 80 and 120,inclusive, with a scores of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items:

    1. Item 1 (P1; delusions)
    2. Item 2 (P2; conceptual disorganization)
    3. Item 3 (P3; hallucinatory behavior)
    4. Item 6 (P6; suspiciousness/persecution)
  6. Subjects with no change (improvement) in PANSS total score between screening and baseline (Day -1) of more than 20%.
  7. Subject has a CGI-S score of ≥4 at screening and baseline (Day -1) visits.
  8. Subject will have been off lithium therapy for at least 2 weeks before baseline and free of all oral antipsychotic medications for at least 5 half-lives or 1 week, whichever is longer, before baseline (Day -1).
  9. Subjects taking a long-acting injectable antipsychotic could not have received a dose of medication for at least 12 weeks (24 weeks for INVEGA TRINZA®) before baseline visit (Day -1).
  10. Subject is able to be confined to an inpatient setting for the duration of the 5-week double-blind part of the study, follow instructions, and comply with the protocol requirements.
  11. of 18 to 40 kg/m2, inclusive.
  12. Subject resides in a stable living situation and is anticipated to return to that same stable living situation after discharge, in the opinion of the investigator.
  13. Subject has an identified reliable informant. An informant is needed at the screening and baseline visits as well as at the end of the study for relevant assessments (site staff may act as informant while the subject is an inpatient). An informant may not be necessary if the subject has been a patient of the investigator for ≥1 year.
  14. Women of (WOCBP) or men whose sexual partners are WOCBP must be willing and able to adhere to the guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening).
  2. Subjects who are newly diagnosed or are experiencing their first treated episode of schizophrenia.
  3. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  4. Subjects with (HIV), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or liver function test results.
  5. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
  6. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months.
  7. Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and C-SSRS.
  8. Clinically significant abnormal findings on the physical examination, medical history, , or clinical laboratory results at screening that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  9. Subjects are receiving or have recently received (within 5 half-lives or 1 week, whichever is longer, before baseline [Day -1]) oral antipsychotic medications; monoamine oxidase inhibitors; anticonvulsants (e.g., lamotrigine, valproate); tricyclic antidepressants (e.g., imipramine, desipramine); selective serotonin reuptake inhibitors; or any other psychoactive medications except for as-needed anxiolytics (e.g., lorazepam, chloral hydrate).
  10. Subjects are receiving or have recently received (within 1 week before baseline [Day -1]) metformin.
  11. Pregnant, lactating, or less than 3 months postpartum.
  12. In the opinion of the investigator and/or Sponsor, subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the investigator and/or Sponsor, may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements.
  13. Subject has had psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before screening.
  14. Subject has a history of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) or has required clozapine within the last 12 months.
  15. Subjects with prior exposure to KarXT.
  16. Subjects who experienced any significant adverse effects due to trospium chloride.
  17. Participation in another clinical study within 3 months before screening in which the subject received an experimental or drug agent.
  18. Significant risk of violent or destructive behavior.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.

    Also known as: KarXT

  • DrugPlacebo

    Placebo Capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period

    PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

    Time frame: At Baseline and at Week 5 of the Double-Blind Period

Secondary outcomes

  1. Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period

    The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

    Time frame: At Baseline and at Week 5 of the Double-Blind Period

  2. Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period

    The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

    Time frame: At Baseline and at Week 5 of the Double-Blind Period

  3. Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period

    The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

    Time frame: At Baseline and at Week 5 of the Double-Blind Period

  4. Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 5 of the Double-Blind Period

    The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

    Time frame: At Baseline and at Week 5 of the Double-Blind Period

  5. Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 5 of the Double-Blind Period

    PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

    Time frame: At Baseline and at Week 5 of the Double-Blind Period

  6. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 12 of the Open-Label Period

    PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At Baseline and at Week 12 of the Open-Label Period

  7. Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period

    The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At Baseline and at Week 12 of the Open-Label Period

  8. Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period

    The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At Baseline and at Week 12 of the Open-Label Period

  9. Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period

    The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At Baseline and at Week 12 of the Open-Label Period

  10. Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 12 of the Open-Label Period

    The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At Baseline and at Week 12 of the Open-Label Period

  11. Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 12 of the Open-Label Period

    PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At Baseline and at Week 12 of the Open-Label Period

  12. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Drug Withdrawal

    Adverse Event (AE): An AE is any unfavorable and unintended sign, symptom, or disease that occurs in a participant during a clinical trial, regardless of whether it is related to the study treatment. This includes new conditions or worsening of pre-existing ones. Serious Adverse Event (SAE): An SAE is an AE that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, causes persistent or significant disability/incapacity, or leads to a congenital anomaly/birth defect. Other events may be considered serious if they require medical intervention to prevent one of these outcomes.

    Time frame: From first dose until study completion (up to approximately 18 weeks)

  13. Number of Participants With Orthostatic Vital Sign Events

    Orthostatic vital signs included blood pressure and heart rate. A participant having sustained orthostatic event is defined as the participant experienced at least one orthostatic event for at least 3 consecutive visits.

    Time frame: From first dose until study completion (up to approximately 18 weeks)

  14. Number of Participants With Elevated Liver Function Test Results

    ULN = upper limit of normal range.; DB = Double-blind period; OL = Open-label period. Hy's law is defined as an elevated alanine aminotransferase level (\>3xULN) or an elevated aspartate aminotransferase (\>3xULN) in combination with alkaline phosphatase \<2xULN and elevated total bilirubin (\>2 x ULN). Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At study baseline, Day 21 DB, Day 35 DB, open-label baseline, Day 14 OL, Day 84 OL, and end of study visit (up to approximately 18 weeks)

  15. Number of Participants With Elevated Metabolic Syndrome Parameters

    ULN = Upper limit of normal; DB = Double-blind period; OL = Open-label period. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At study baseline, Day 21 DB, Day 35 DB, open-label baseline, Day 14 OL, Day 84 OL, and end of study visit (up to approximately 18 weeks)

  16. Number of Participants With Abnormal Electrocardiogram (ECG) Results

    Anytime post-baseline includes all assessments from the first dose of study drug until end of study visit in double-blind/open-label part, including unscheduled assessments. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At study baseline and up to study completion (up to approximately 18 weeks)

  17. Number of Participants With Suicidal Ideation as Defined by a Columbia-Suicide Severity Rating Scale (C-SSRS) Ideation Score of 1 or Greater

    The C-SSRS is a clinician- or self-administered questionnaire assessing suicidal ideation and behavior. It rates ideation severity from 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). It also records the presence or absence of suicidal behaviors, including actual, interrupted, or aborted attempts, and preparatory acts. The highest level of ideation or most severe behavior reported is used to determine suicide risk; higher ideation scores or any suicidal behavior indicate greater risk. Baseline is the last non-missing assessment before first study drug dose.

    Time frame: From first dose to study completion (up to approximately 18 weeks)

  18. Number of Participants With Clinically Meaningful Changes in Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS) Results

    Treatment-emergent parkinsonism is defined as Simpson-Angus Scale total score \>3 with a baseline score ≤3. Treatment-emergent akathisia is defined as Barnes Akathisia Rating Scale global clinical assessment score \>2 with a baseline score ≤2. Treatment-emergent dyskinesia is defined as any Abnormal Involuntary Movement Scale (AIMS) item 1-7 score ≥3 with a baseline score \<3 for the item, or score ≥2 on two or more of AIMS items 1-7 with baseline \<2 for the items. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At study baseline, open-label baseline, and up to study completion (up to approximately 18 weeks)

  19. Change From Baseline in Body Weight

    Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 weeks)

  20. Change From Baseline in Body Mass Index (BMI)

    Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 weeks)

  21. Change From Baseline in Waist Circumference

    Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

    Time frame: At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 months)

  22. Area Under the Concentration-Time Curve (AUC0-12) of Xanomeline and Trospium - Double-Blind Period

    AUC₀-12 (Area Under the Concentration-Time Curve from time zero to 12 hours) is the total amount of drug in the blood measured from the time the drug is given (time zero) up to 12 hours after dosing.

    Time frame: On Day 28 of the Double-Blind Period

  23. Maximum Observed Plasma Concentration (Cmax) of Xanomeline and Trospium - Double-Blind Period

    Cmax is the highest concentration of a drug measured in the blood after it is given.

    Time frame: On Day 28 of the Double-Blind Period

  24. Time to Cmax (Tmax) of Xanomeline and Trospium - Double-Blind Period

    Tmax is the amount of time it takes to reach that highest concentration (Cmax) after the drug is given.

    Time frame: On Day 28 of the Double-Blind Period

07

Results

Posted Nov 21, 2025

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestoneDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Started1039900
Completed1029800
Not completed1100
Withdrew: Screen failure1000
Withdrew: Protocol violation0100
Double-Blind Period
Participant flow — Double-Blind Period
MilestoneDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Started1029800
Completed797800
Not completed232000
Withdrew: Adverse event8900
Withdrew: Protocol violation2100
Withdrew: Participant withdrew consent11700
Withdrew: Other reasons2300
Open Label Period
Participant flow — Open Label Period
MilestoneDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Started003828
Completed001811
Not completed002017
Withdrew: Adverse event0024
Withdrew: Lost to follow-up0010
Withdrew: Protocol violation0001
Withdrew: Participant withdrew consent0086
Withdrew: Death0001
Withdrew: Other reasons0095

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period

PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

Time frame:
At Baseline and at Week 5 of the Double-Blind Period
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period
Score on a ScaleDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period-16.9 ± 2.122-7.7 ± 2.074
Statistical analysis
  • Double-Blind Part: KarXT vs Double-Blind Part: Placebo · Mixed model repeated measure · p = 0.0014 · Least-squares mean difference: -9.2 · 95% CI -14.8 to -3.6Numerator=KarXT/KarXT, denominator =Placebo/KarXT
SecondaryChange From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period

The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

Time frame:
At Baseline and at Week 5 of the Double-Blind Period
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
Score on a ScaleDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period-6.5 ± 0.713-4.6 ± 0.700
Statistical analysis
  • Double-Blind Part: KarXT vs Double-Blind Part: Placebo · Mixed model for Repeated measures · p = 0.0474 · Least-squares mean difference: -1.9 · 95% CI -3.8 to 0Numerator=KarXT/KarXT, denominator =Placebo/KarXT
SecondaryChange From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period

The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

Time frame:
At Baseline and at Week 5 of the Double-Blind Period
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
Score on a ScaleDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period-3.2 ± 0.664-0.7 ± 0.648
Statistical analysis
  • Double-Blind Part: KarXT vs Double-Blind Part: Placebo · Mixed model for Repeated measures · p = 0.0062 · Least-squares mean difference: -2.5 · 95% CI -4.2 to -0.7includes PANSS change at Weeks 2-5; fixed effects: treatment, visit, interaction; covariates: site, age, sex, baseline PANSS positive symptom score.
SecondaryChange From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period

The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

Time frame:
At Baseline and at Week 5 of the Double-Blind Period
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
Score on a ScaleDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period-3.1 ± 0.677-0.5 ± 0.660
Statistical analysis
  • Double-Blind Part: KarXT vs Double-Blind Part: Placebo · Mixed model for Repeated measures · p = 0.0056 · Least-squares mean difference: -2.5 · 95% CI -4.3 to -0.8includes PANSS change at Weeks 2-5; fixed effects: treatment, visit, interaction; covariates: site, age, sex, baseline PANSS positive symptom score.
SecondaryChange From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 5 of the Double-Blind Period

The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

Time frame:
At Baseline and at Week 5 of the Double-Blind Period
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 5 of the Double-Blind Period
Score on a ScaleDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 5 of the Double-Blind Period-0.9 ± 0.119-0.5 ± 0.117
Statistical analysis
  • Double-Blind Part: KarXT vs Double-Blind Part: Placebo · Mixed model for repeated measures · p = 0.0208 · Least-squares mean difference: -0.4 · 95% CI -0.7 to -0.1ncludes PANSS change at Weeks 2-5; fixed effects: treatment, visit, interaction; covariates: site, age, sex, baseline PANSS positive symptom score.
SecondaryPercentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 5 of the Double-Blind Period

PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

Time frame:
At Baseline and at Week 5 of the Double-Blind Period
Reported as:
Number · Percentage of participants
Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 5 of the Double-Blind Period
Percentage of participantsDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 5 of the Double-Blind Period42.126.3
Statistical analysis
  • Double-Blind Part: KarXT vs Double-Blind Part: Placebo · Chi-squared · p = 0.0402 · Percentage difference: 15.8 · 95% CI 0.7 to 29.9
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 12 of the Open-Label Period

PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At Baseline and at Week 12 of the Open-Label Period
Reported as:
Mean · Score on a Scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 12 of the Open-Label Period
Score on a ScaleOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study baseline to Open-label period- Week 12-22.0 ± 21.67-21.2 ± 19.76
Open-label period- baseline to Open-label period- Week 12-2.7 ± 17.27-6.1 ± 12.49
SecondaryChange From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period

The PANSS Positive Symptom Score assesses the severity of positive symptoms in schizophrenia, such as hallucinations and delusions. It includes 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At Baseline and at Week 12 of the Open-Label Period
Reported as:
Mean · Score on a Scale
Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period
Score on a ScaleOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study baseline to Open-label period - Week 12-6.9 ± 6.09-8.2 ± 6.65
Open-label period- baseline to Open-label period- Week 12-0.2 ± 5.31-0.8 ± 4.64
SecondaryChange From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period

The Positive and Negative Syndrome Scale (PANSS) Negative Symptom Score assesses the severity of negative symptoms in schizophrenia, such as emotional withdrawal and reduced motivation. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. Each item is rated from 1 (absent) to 7 (extreme), for a total score range of 7 to 49. Higher scores indicate more severe symptoms and worse outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At Baseline and at Week 12 of the Open-Label Period
Reported as:
Mean · Score on a Scale
Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period
Score on a ScaleOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study baseline to Open-label period- Week 12-4.3 ± 7.75-3.0 ± 7.40
Open-label period- baseline to Open-label period- Week 12-0.4 ± 5.64-1.4 ± 4.88
SecondaryChange From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period

The Negative Marder Factor Score is subset of PANSS items used to evaluate negative symptoms based on a five-factor model. It includes 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity, motor retardation, and active social avoidance. Each item is rated from 1 to 7. Higher scores reflect greater severity of negative symptoms and poorer clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At Baseline and at Week 12 of the Open-Label Period
Reported as:
Mean · Score on a Scale
Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 12 of the Open-Label Period
Score on a ScaleOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study baseline to Open-label period- Week 12-3.9 ± 7.40-3.0 ± 7.25
Open-label period- baseline to Open-label period- Week 12-0.2 ± 5.43-0.8 ± 4.49
SecondaryChange From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 12 of the Open-Label Period

The CGI-S Score is a clinician-rated scale used to assess the severity of a patient's mental illness at a given time. It ranges from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). The score reflects the clinician's overall impression based on observed symptoms, behavior, and functioning. Higher scores indicate greater illness severity and worse clinical status. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At Baseline and at Week 12 of the Open-Label Period
Reported as:
Mean · Score on a Scale
Change From Baseline in Clinical Global Impressions - Severity (CGI-S) Score at Week 12 of the Open-Label Period
Score on a ScaleOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study baseline to Open-label period- Week 12-1.1 ± 1.06-1.2 ± 0.98
Open-label period- baseline to Open-label period- Week 12-0.1 ± 0.80-0.5 ± 0.82
SecondaryPercentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 12 of the Open-Label Period

PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At Baseline and at Week 12 of the Open-Label Period
Reported as:
Number · Percentage of participants
Percentage of PANSS Responders (≥30% Change in PANSS Total Score From Baseline) at Week 12 of the Open-Label Period
Percentage of participantsOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study baseline to Open-label period- Week 1266.745.5
Open-label period- baseline to Open-label period- Week 1216.727.3
SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Drug Withdrawal

Adverse Event (AE): An AE is any unfavorable and unintended sign, symptom, or disease that occurs in a participant during a clinical trial, regardless of whether it is related to the study treatment. This includes new conditions or worsening of pre-existing ones. Serious Adverse Event (SAE): An SAE is an AE that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, causes persistent or significant disability/incapacity, or leads to a congenital anomaly/birth defect. Other events may be considered serious if they require medical intervention to prevent one of these outcomes.

Time frame:
From first dose until study completion (up to approximately 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Drug Withdrawal
ParticipantsDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Adverse events97903328
Serious adverse events0303
Adverse events leading to drug withdrawal8924
SecondaryNumber of Participants With Orthostatic Vital Sign Events

Orthostatic vital signs included blood pressure and heart rate. A participant having sustained orthostatic event is defined as the participant experienced at least one orthostatic event for at least 3 consecutive visits.

Time frame:
From first dose until study completion (up to approximately 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Orthostatic Vital Sign Events
ParticipantsDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Orthostatic event at any visit363185
A Decrease in Systolic Blood Pressure of ≥ 20 mmHg211022
A Decrease in Diastolic Blood Pressure of ≥ 10 mmHg161645
An Increase in Heart Rate of ≥ 30 bpm91220
Sustained orthostatic events3200
SecondaryNumber of Participants With Elevated Liver Function Test Results

ULN = upper limit of normal range.; DB = Double-blind period; OL = Open-label period. Hy's law is defined as an elevated alanine aminotransferase level (\>3xULN) or an elevated aspartate aminotransferase (\>3xULN) in combination with alkaline phosphatase \<2xULN and elevated total bilirubin (\>2 x ULN). Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At study baseline, Day 21 DB, Day 35 DB, open-label baseline, Day 14 OL, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Elevated Liver Function Test Results
ParticipantsDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study Baseline - Alanine aminotransferase - >3XULN0000
Study Baseline - Alanine aminotransferase - >5XULN0000
Study Baseline - Alanine aminotransferase - >8XULN0000
Study Baseline - Alanine aminotransferase - >10XULN0000
Study Baseline - Alanine aminotransferase - >20XULN0000
Study Baseline - Aspartate Aminotransferase - >3XULN0000
Study Baseline - Aspartate Aminotransferase - >5XULN0000
Study Baseline - Aspartate Aminotransferase - >8XULN0000
Study Baseline - Aspartate Aminotransferase - >10XULN0000
Study Baseline - Aspartate Aminotransferase - >20XULN0000
Study Baseline - Alkaline phosphatase - >1.5XULN0000
Study Baseline - Alkaline phosphatase - >2XULN0000
Study Baseline - Bilirubin - >1.5XULN0201
Study Baseline - Bilirubin - >2XULN0000
Study Baseline - Gamma glutamyl transferase - >2XULN1110
Study Baseline - Hy's law cases0000
Day 21 DB - Alanine aminotransferase - >3XULN50——
Day 21 DB - Alanine aminotransferase - >5XULN20——
Day 21 DB - Alanine aminotransferase - >8XULN10——
Day 21 DB - Alanine aminotransferase - >10XULN00——
Day 21 DB - Alanine aminotransferase - >20XULN00——
Day 21 DB - Aspartate Aminotransferase - >3XULN10——
Day 21 DB - Aspartate Aminotransferase - >5XULN10——
Day 21 DB- Aspartate Aminotransferase - >8XULN10——
Day 21 DB - Aspartate Aminotransferase - >10XULN10——
Day 21 DB - Aspartate Aminotransferase - >20XULN00——
Day 21 DB - Alkaline phosphatase - >1.5XULN20——
Day 21 DB - Alkaline phosphatase - >2XULN00——
Day 21 DB - Bilirubin - >1.5XULN02——
Day 21 DB - Bilirubin - >2XULN00——
Day 21 DB - Gamma glutamyl transferase - >2XULN91——
Day 21 DB - Hy's law cases00——
Day 35 DB - Alanine aminotransferase - >3XULN01——
Day 35 DB - Alanine aminotransferase - >5XULN00——
Day 35 DB - Alanine aminotransferase - >8XULN00——
Day 35 DB - Alanine aminotransferase - >10XULN00——
Day 35 DB - Alanine aminotransferase - >20XULN00——
Day 35 DB - Aspartate Aminotransferase - >3XULN00——
Day 35 DB - Aspartate Aminotransferase - >5XULN00——
Day 35 DB - Aspartate Aminotransferase - >8XULN00——
Day 35 DB - Aspartate Aminotransferase - >10XULN00——
Day 35 DB - Aspartate Aminotransferase - >20XULN00——
Day 35 DB - Alkaline phosphatase - >1.5XULN01——
Day 35 DB - Alkaline phosphatase - >2XULN01——
Day 35 DB - Bilirubin - >1.5XULN04——
Day 35 DB - Bilirubin - >2XULN00——
Day 35 DB - Gamma glutamyl transferase - >2XULN32——
Day 35 DB - Hy's law cases00——
End of study - Alanine aminotransferase - >3XULN0000
End of study - Alanine aminotransferase - >5XULN0000
End of study - Alanine aminotransferase - >8XULN0000
End of study - Alanine aminotransferase - >10XULN0000
End of study - Alanine aminotransferase - >20XULN0000
End of study - Aspartate Aminotransferase - >3XULN0000
End of study - Aspartate Aminotransferase - >5XULN0000
End of study - Aspartate Aminotransferase - >8XULN0000
End of study - Aspartate Aminotransferase - >10XULN0000
End of study - Aspartate Aminotransferase - >20XULN0000
End of study - Alkaline phosphatase - >1.5XULN0100
End of study - Alkaline phosphatase - >2XULN0000
End of study - Bilirubin - >1.5XULN0000
End of study - Bilirubin - >2XULN0000
End of study - Gamma glutamyl transferase - >2XULN1100
End of study - Hy's law cases0000
Open-label baseline - Alanine aminotransferase - >3XULN——00
Open-label baseline - Alanine aminotransferase - >5XULN——00
Open-label baseline - Alanine aminotransferase - >8XULN——00
Open-label baseline - Alanine aminotransferase - >10XULN——00
Open-label baseline - Alanine aminotransferase - >20XULN——00
Open-label baseline - Aspartate Aminotransferase - >3XULN——00
Open-label baseline - Aspartate Aminotransferase - >5XULN——00
Open-label baseline - Aspartate Aminotransferase - >8XULN——00
Open-label baseline - Aspartate Aminotransferase - >10XULN——00
Open-label baseline - Aspartate Aminotransferase - >20XULN——00
Open-label baseline - Alkaline phosphatase - >1.5XULN——00
Open-label baseline - Alkaline phosphatase - >2XULN——00
Open-label baseline - Bilirubin - >1.5XULN——00
Open-label baseline - Bilirubin - >2XULN——00
Open-label baseline - Gamma glutamyl transferase - >2XULN——10
Open-label baseline - Hy's law cases——00
Day 14 OL - Alanine aminotransferase - >3XULN——10
Day 14 OL - Alanine aminotransferase - >5XULN——00
Day 14 OL - Alanine aminotransferase - >8XULN——00
Day 14 OL - Alanine aminotransferase - >10XULN——00
Day 14 OL - Alanine aminotransferase - >20XULN——00
Day 14 OL - Aspartate Aminotransferase - >3XULN——00
Day 14 OL - Aspartate Aminotransferase - >5XULN——00
Day 14 OL - Aspartate Aminotransferase - >8XULN——00
Day 14 OL - Aspartate Aminotransferase - >10XULN——00
Day 14 OL - Aspartate Aminotransferase - >20XULN——00
Day 14 OL - Alkaline phosphatase - >1.5XULN——00
Day 14 OL - Alkaline phosphatase - >2XULN——00
Day 14 OL - Bilirubin - >1.5XULN——00
Day 14 OL - Bilirubin - >2XULN——00
Day 14 OL - Gamma glutamyl transferase - >2XULN——10
Day 14 OL - Hy's law cases——00
Day 84 - OL - Alanine aminotransferase - >3XULN——00
Day 84 - OL - Alanine aminotransferase - >5XULN——00
Day 84 - OL - Alanine aminotransferase - >8XULN——00
Day 84 - OL - Alanine aminotransferase - >10XULN——00
Day 84 - OL - Alanine aminotransferase - >20XULN——00
Day 84 - OL - Aspartate Aminotransferase - >3XULN——00
Day 84 - OL - Aspartate Aminotransferase - >5XULN——00
Day 84 - OL - Aspartate Aminotransferase - >8XULN——00
Day 84 - OL - Aspartate Aminotransferase - >10XULN——00
Day 84 - OL - Aspartate Aminotransferase - >20XULN——00
Day 84 - OL - Alkaline phosphatase - >1.5XULN——00
Day 84 - OL - Alkaline phosphatase - >2XULN——00
Day 84 - OL - Bilirubin - >1.5XULN——00
Day 84 - OL - Bilirubin - >2XULN——00
Day 84 - OL - Gamma glutamyl transferase - >2XULN——00
Day 84 - OL - Hy's law cases——00
SecondaryNumber of Participants With Elevated Metabolic Syndrome Parameters

ULN = Upper limit of normal; DB = Double-blind period; OL = Open-label period. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At study baseline, Day 21 DB, Day 35 DB, open-label baseline, Day 14 OL, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Elevated Metabolic Syndrome Parameters
ParticipantsDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Study baseline - Glucose > ULN141868
Study baseline - Total Cholesterol > ULN191165
Study baseline - Triglycerides > ULN182058
Day 21 DB - Glucose > ULN108——
Day 21 DB - Total Cholesterol > ULN76——
Day 21 DB - Triglycerides > ULN1922——
Day 35 DB - Glucose > ULN1212——
Day 35 DB - Total Cholesterol > ULN78——
Day 35 DB - Triglycerides > ULN1825——
End of study - Glucose > ULN6713
End of study - Total Cholesterol > ULN5441
End of study - Triglycerides > ULN81424
Open-label baseline - Glucose > ULN——63
Open-label baseline - Total Cholesterol > ULN——12
Open-label baseline - Triglycerides > ULN——96
Day 14 OL - Glucose > ULN——55
Day 14 OL - Total Cholesterol > ULN——32
Day 14 OL - Triglycerides > ULN——83
Day 84 OL - Glucose > ULN——12
Day 84 OL - Total Cholesterol > ULN——21
Day 84 OL - Triglycerides > ULN——22
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Results

Anytime post-baseline includes all assessments from the first dose of study drug until end of study visit in double-blind/open-label part, including unscheduled assessments. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At study baseline and up to study completion (up to approximately 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Results
ParticipantsDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Baseline - QTcF > 450 msec3030
Baseline - QTcF > 480 msec0000
Baseline - QTcF > 500 msec0000
Baseline - PR ≥ 250 msec0000
Baseline - QRS Interval ≥ 150 msec0000
Anytime post baseline - QTcF > 450 msec2210
Anytime post baseline - QTcF > 480 msec0010
Anytime post baseline - QTcF > 500 msec0000
Anytime post baseline - QTcF Increase > 30 msec from study baseline172146
Anytime post baseline - QTcF Increase > 60 msec from study baseline2002
Anytime post baseline - QTcF Increase > 30 msec from open-label baseline——46
Anytime post baseline - PR ≥ 250 msec0000
Anytime post baseline - QTcF Increase > 60 msec from open-label baseline——10
Anytime post baseline - QRS Interval ≥ 150 msec1000
SecondaryNumber of Participants With Suicidal Ideation as Defined by a Columbia-Suicide Severity Rating Scale (C-SSRS) Ideation Score of 1 or Greater

The C-SSRS is a clinician- or self-administered questionnaire assessing suicidal ideation and behavior. It rates ideation severity from 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). It also records the presence or absence of suicidal behaviors, including actual, interrupted, or aborted attempts, and preparatory acts. The highest level of ideation or most severe behavior reported is used to determine suicide risk; higher ideation scores or any suicidal behavior indicate greater risk. Baseline is the last non-missing assessment before first study drug dose.

Time frame:
From first dose to study completion (up to approximately 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation as Defined by a Columbia-Suicide Severity Rating Scale (C-SSRS) Ideation Score of 1 or Greater
ParticipantsDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Post-Baseline Suicidal ideation (SI) - Any Suicidal Ideation7413
Post-Baseline Suicidal ideation - Wish to be Dead5413
Post-Baseline Suicidal ideation - Non-Specific Active Suicidal Thoughts6311
Post-Baseline SI - Active Suicidal Ideation with any Methods without Intent to Act1201
Post-Baseline SI - Active Suicidal Ideation with Some Intent to Act without Specific Plan1101
Post-Baseline Suicidal ideation - Active Suicidal Ideation with Specific Plan and Intent1001
SecondaryNumber of Participants With Clinically Meaningful Changes in Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS) Results

Treatment-emergent parkinsonism is defined as Simpson-Angus Scale total score \>3 with a baseline score ≤3. Treatment-emergent akathisia is defined as Barnes Akathisia Rating Scale global clinical assessment score \>2 with a baseline score ≤2. Treatment-emergent dyskinesia is defined as any Abnormal Involuntary Movement Scale (AIMS) item 1-7 score ≥3 with a baseline score \<3 for the item, or score ≥2 on two or more of AIMS items 1-7 with baseline \<2 for the items. Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At study baseline, open-label baseline, and up to study completion (up to approximately 18 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes in Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS) Results
ParticipantsDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Treatment-Emergent Parkinsonism with respect to study baseline3211
Treatment-Emergent Akathisia with respect to study baseline2300
Treatment-Emergent Dyskinesia with respect to study baseline0201
Treatment-Emergent Parkinsonism with respect to open-label baseline——20
Treatment-Emergent Akathisia with respect to open-label baseline——00
Treatment-Emergent Dyskinesia with respects to open-label baseline——01
SecondaryChange From Baseline in Body Weight

Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Reported as:
Mean · Kg
Change From Baseline in Body Weight
KgDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Day 35 change from study baseline-2.125 ± 2.9596-1.184 ± 3.1079——
Day 84 change from study baseline——-2.889 ± 6.7846-6.955 ± 5.0021
Day 84 change from open-label baseline——-1.222 ± 5.2847-4.182 ± 2.9634
End of study change from study baseline-2.773 ± 3.1119-0.646 ± 3.3921-2.533 ± 6.4198-4.995 ± 5.2225
End of study change from open-label baseline——-1.462 ± 5.1589-2.850 ± 3.2432
SecondaryChange From Baseline in Body Mass Index (BMI)

Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 weeks)
Reported as:
Mean · Kg/m2
Change From Baseline in Body Mass Index (BMI)
Kg/m2Double-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Day 35/Week 5 Change from Study baseline-0.79 ± 1.106-0.43 ± 1.135——
Day 84/Week 12 Change from Study baseline——-1.10 ± 2.692-2.61 ± 1.983
Day 84/Week 12 Change from open-label baseline——-0.46 ± 2.1211.59 ± 1.276
End of Study Change from Study baseline-1.01 ± 1.133-0.22 ± 1.193-0.92 ± 2.499-1.83 ± 1.930
End of Study Change from open-label baseline——-0.52 ± 2.046-1.05 ± 1.224
SecondaryChange From Baseline in Waist Circumference

Study baseline is defined as last non-missing assessment prior to the first dose of study drug. Open-label baseline is defined as last non-missing assessment prior to the first dose of study drug in the open-label part.

Time frame:
At study baseline, Day 35 DB, open-label baseline, Day 84 OL, and end of study visit (up to approximately 18 months)
Reported as:
Mean · cm
Change From Baseline in Waist Circumference
cmDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
Day 35/Week 5 Change from Study baseline-2.27 ± 4.070-1.01 ± 3.269——
Day 84/Week 12 Change from Study baseline——-3.96 ± 8.288-4.82 ± 6.416
Day 84/Week 12 Change from open-label baseline——-1.88 ± 7.198-2.27 ± 4.671
End of Study Change from Study baseline-3.40 ± 4.155-1.34 ± 4.167-4.69 ± 8.183-3.39 ± 5.345
End of Study Change from open-label baseline——-3.12 ± 6.874-2.45 ± 2.543
SecondaryArea Under the Concentration-Time Curve (AUC0-12) of Xanomeline and Trospium - Double-Blind Period

AUC₀-12 (Area Under the Concentration-Time Curve from time zero to 12 hours) is the total amount of drug in the blood measured from the time the drug is given (time zero) up to 12 hours after dosing.

Time frame:
On Day 28 of the Double-Blind Period
Reported as:
Geometric mean · pg*h/mL
Area Under the Concentration-Time Curve (AUC0-12) of Xanomeline and Trospium - Double-Blind Period
pg*h/mLDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Day 28 - Xanomeline 100/2093200 ± 89.9—
Day 28 - Xanomeline 125/3087100 ± 75.9—
Day 28 - Trospium 100/2048600 ± 70.4—
Day 28 - Trospium 125/3047900 ± 81.9—
SecondaryMaximum Observed Plasma Concentration (Cmax) of Xanomeline and Trospium - Double-Blind Period

Cmax is the highest concentration of a drug measured in the blood after it is given.

Time frame:
On Day 28 of the Double-Blind Period
Reported as:
Geometric mean · pg/mL
Maximum Observed Plasma Concentration (Cmax) of Xanomeline and Trospium - Double-Blind Period
pg/mLDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Day 28 - Xanomeline 100/2016000 ± 129.1—
Day 28 - Xanomeline 125/3015900 ± 95.9—
Day 28 - Trospium 100/2011100 ± 139.7—
Day 28 - Trospium 125/309330 ± 99.3—
SecondaryTime to Cmax (Tmax) of Xanomeline and Trospium - Double-Blind Period

Tmax is the amount of time it takes to reach that highest concentration (Cmax) after the drug is given.

Time frame:
On Day 28 of the Double-Blind Period
Reported as:
Geometric mean · Hours
Time to Cmax (Tmax) of Xanomeline and Trospium - Double-Blind Period
HoursDouble-Blind Part: KarXTDouble-Blind Part: Placebo
Day 28 - Xanomeline 100/201.70 (0.00 to 11.97)—
Day 28 - Xanomeline 125/301.93 (0.00 to 11.95)—
Day 28 - Trospium 100/200.56 (0.00 to 11.90)—
Day 28 - Trospium 125/300.97 (0.42 to 2.07)—

Adverse events

Collected over Double-blind part: From the start of study drug administration up to week 5. Open-label extension part: From the start of study drug administration up to week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Part: KarXT0/103 (0%)0/102 (0%)97/102 (95.1%)
Double-Blind Part: Placebo0/99 (0%)3/98 (3.1%)90/98 (91.8%)
Open-Label Part: KarXT/KarXT0/38 (0%)0/38 (0%)33/38 (86.8%)
Open-Label Part: Placebo/KarXT1/28 (3.6%)3/28 (10.7%)28/28 (100%)
Most frequent serious events
Most frequent serious events
EventDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
SchizophreniaPsychiatric disorders0/1022/980/382/28
Completed suicidePsychiatric disorders0/1020/980/381/28
Suicidal ideationPsychiatric disorders0/1020/980/381/28
Spinal compression fractureInjury, poisoning and procedural complications0/1021/980/380/28
Most frequent other events
Showing 10 of 39
Most frequent other events
EventDouble-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXT
VomitingGastrointestinal disorders48/1022/9810/3820/28
NauseaGastrointestinal disorders38/1025/985/3814/28
Weight decreasedInvestigations21/10216/9811/3810/28
ConstipationGastrointestinal disorders32/10220/986/388/28
Decreased appetiteMetabolism and nutrition disorders8/1024/981/387/28
TachycardiaCardiac disorders20/1022/982/383/28
DizzinessNervous system disorders20/1025/981/383/28
Sinus tachycardiaCardiac disorders17/1022/980/383/28
Orthostatic hypotensionVascular disorders16/10214/984/383/28
DiarrhoeaGastrointestinal disorders12/1023/982/384/28

Baseline characteristics

Open-Label participants are accounted for under their Double-Blind Groups

Age, Continuous
Age, Continuous(Years)Double-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXTTotal
Mean37.3 ± 9.5536.9 ± 11.91——37.1 ± 10.75
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXTTotal
Female5650——106
Male4749——96
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXTTotal
Hispanic or Latino00——0
Not Hispanic or Latino10399——202
Unknown or Not Reported00——0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind Part: KarXTDouble-Blind Part: PlaceboOpen-Label Part: KarXT/KarXTOpen-Label Part: Placebo/KarXTTotal
American Indian or Alaska Native00——0
Asian10399——202
Native Hawaiian or Other Pacific Islander00——0
Black or African American00——0
White00——0
More than one race00——0
Unknown or Not Reported00——0
08

Study locations

28 sites
  • Anhui Mental Health Center
    Hefei, Anhui 230022, China
  • Wuhu Hospital of Beijing Anding Hospital
    Wuhu, Anhui 241000, China
  • Beijing Anding Hospital Capital Medical University
    Beijing, Beijing Municipality 100035, China
  • Peking University Sixth Hospital
    Beijing, Beijing Municipality 100083, China
  • Beijing HuiLongGuan Hospital
    Changping, Beijing Municipality 100096, China
  • Chongqing 11th People's Hospital
    Chongqing, Chongqing Municipality 400047, China
  • Chongqing Mental Health Center
    Jiangbei, Chongqing Municipality 401147, China
  • The Affiliated Brain Hospital of Guangzhou Medical University
    Guanzhou, Guangdong 510370, China
  • The Sixth People's Hosptial of Hebei Province
    Baoding, Hebei 071051, China
  • Daqing City Third Hospital
    Daqing, Heilongjiang 163161, China
  • Zhumadian Second People's Hospital
    Zhumadian, Henan 463001, China
  • Wuhan Mental Health Center
    Wuhan, Hubei 430000, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430064, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Wuxi Mental Health Center
    Wuxi, Jiangsu 214151, China
  • Jiangxi Mental Health Center
    Nanchang, Jiangxi 330027, China
  • Mental Health Center of Xi'an City
    Xi'an, Shaanxi 710061, China
  • Shandong Mental Health Center
    Jinan, Shandong 250014, China
  • Shandong Daizhuang Hospital
    Jining, Shandong 272009, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality 200032, China
  • The Fourth People's Hospital of Chengdu
    Chengdu, Sichuan 610036, China
  • Guangyuan Mental Health Center
    Guangyuan, Sichuan 628033, China
  • Tianjin Anding Hospital
    Tianjin, Tianjin Municipality 300382, China
  • Urumqi Fourth People's Hospital
    Ürümqi, Xinjiang 830002, China
  • Hangzhou Seventh People's Hospital
    Hangzhou, Zhejiang 310013, China
  • HuZhou Third Municipal Hospital
    Huzhou, Zhejiang 313028, China
  • Ningbo Kangning Hospital
    Ningbo, Zhejiang 315002, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325015, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Sep 2024, 15 months.

Results were first posted in Nov 2025, 1 year 2 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 15 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jun 26, 2023
StartActual
May 29, 2023
Primary completionActual
Sep 16, 2024
CompletionActual
Dec 9, 2024
Results first posted
Nov 21, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05919823
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
May 29, 2023
Primary completion
Sep 16, 2024
Completion
Dec 9, 2024
Results posted
Nov 21, 2025
Last update
Dec 17, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion